Lehtisalo, M., Keskitalo, J. E., Tornio, A., Lapatto‐Reiniluoto, O., Deng, F., Jaatinen, T., . . . Niemi, M. (2020). Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. Clin Transl Sci.
Chicago Style CitationLehtisalo, Minna, et al. "Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin." Clin Transl Sci 2020.
Cita MLALehtisalo, Minna, et al. "Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin." Clin Transl Sci 2020.
Atenció: Aquestes cites poden no estar 100% correctes.